Does melasma go away after pregnancy?

Melasma that develops during pregnancy — sometimes called chloasma or the mask of pregnancy — often fades partially or fully in the months after delivery as estrogen and progesterone levels return to baseline. Many women see meaningful improvement by 3–6 months postpartum. However, it does not always resolve completely, particularly if there is significant sun exposure after delivery or a strong genetic predisposition. Strict daily SPF 50 sunscreen use throughout and after pregnancy is the single most effective step to prevent worsening and support fading.

Can the contraceptive pill cause melasma?

Yes. Combined oral contraceptives containing both estrogen and progestogen are a well-established trigger for melasma in susceptible women, because estrogen directly stimulates melanocytes. Progestogen-only pills and hormonal IUDs, which produce minimal systemic estrogen, are much less likely to cause melasma. If melasma develops while on a combined pill, switching to a non-hormonal or progestogen-only method often leads to gradual improvement over several months, though consistent sun protection remains essential regardless of the contraceptive choice.

Is melasma permanent?

Melasma is a chronic, relapsing condition for most people — it can be effectively lightened but tends to return with sun exposure or hormonal changes. This is why ongoing photoprotection matters not just during active treatment but indefinitely. Some people find their melasma fades significantly over years, particularly after menopause when estrogen levels decline naturally. Others require long-term management combining daily SPF 50 sunscreen with periodic use of topical agents such as hydroquinone or azelaic acid.

Yes, though it is uncommon — men account for approximately 10% of melasma cases. When melasma occurs in men, it is thought to be driven primarily by sun exposure and genetic predisposition rather than hormonal fluctuations. The clinical appearance and distribution are the same as in women, and treatment principles are identical: daily broad-spectrum SPF 50 sunscreen is the foundation, with topical depigmenting agents added as needed.

Is melasma treatment covered by provincial health insurance in Canada?

Diagnosis and clinical assessment by a physician or dermatologist are covered under provincial health plans, but most topical treatments for melasma — including prescription hydroquinone, tretinoin, and azelaic acid — are not covered by provincial drug benefit programs and must be paid out of pocket or through private insurance. Procedural treatments such as chemical peels and laser therapy are considered cosmetic and are not covered. Costs vary widely; a dermatology consultation through the public system is free with a referral, while private virtual consultations typically range from $50–$100 CAD.

Melasma — Glossary | Hormone Journal

What it is

Melasma is a common acquired hyperpigmentation disorder affecting roughly 90% women, with chloasma (the mask of pregnancy) occurring in 50–70% of pregnant people. Also called chloasma or the mask of pregnancy, melasma is characterized by symmetrical, irregularly bordered brown to grey-brown patches on sun-exposed areas of the face — most often the cheeks, forehead, upper lip, nose bridge, and chin. The condition arises when melanocytes, the pigment-producing cells in the skin, become overactive and deposit excess melanin in localized areas. Melasma is not dangerous and causes no physical symptoms, but its visible location on the face means it frequently affects self-esteem and quality of life. In Canada, people with darker skin tones (Fitzpatrick types III–VI) — including many South Asian, East Asian, Middle Eastern, Latin American, and Black Canadians — are disproportionately affected and may find the pigmentation more pronounced and more resistant to treatment.

Distribution patterns at a glance

Pattern	Location	Frequency
Centrofacial	Forehead, nose, upper lip, chin	Most common
Malar	Cheeks and nose bridge	Common
Mandibular	Jawline and lower cheeks	Less common
Extrafacial	Forearms, neck	Rare

Causes and mechanism

Three factors interact to produce melasma: hormonal stimulation, UV and visible light exposure, and genetic susceptibility.

Hormonal drivers. Estrogen and progesterone both carry receptors on melanocytes and directly stimulate melanin production. This explains why melasma is so strongly linked to pregnancy (where both hormones peak), combined oral contraceptives (which contain synthetic estrogen and progestogen), and hormone replacement therapy. Melanocyte-stimulating hormone (MSH) also rises during pregnancy and amplifies the effect. Progestogen-only pills and hormonal IUDs, which produce minimal systemic hormone levels, are much less likely to trigger melasma.

UV and visible light. UV radiation is the dominant environmental trigger — it stimulates melanocytes as a protective response, and even modest unprotected sun exposure can initiate or worsen melasma in susceptible individuals. Visible light, particularly blue light from screens and LED sources, has also been shown to drive pigmentation in darker skin types, which has practical implications for Canadians who spend long hours in front of screens indoors.

Genetic factors. A positive family history is common. Certain genetic variants affecting melanocyte regulation increase baseline susceptibility, independent of hormonal status.

Other contributors. Thyroid dysfunction — particularly hypothyroidism — is associated with altered pigmentation. Some antiepileptic medications and phototoxic drugs have also been implicated.

Symptoms and diagnosis

Melasma presents as well-defined patches of hyperpigmentation with a normal skin surface texture. Colour ranges from light to dark brown, grey-brown, or blue-grey. Patches are symmetrical, have irregular but distinct borders, and typically worsen in summer and improve modestly in winter, tracking with UV exposure.

Diagnosis is usually clinical. When the picture is less clear, clinicians use:

Wood's lamp examination — UV light distinguishes epidermal (superficial) from dermal (deeper) pigment. Epidermal melasma shows enhanced contrast under Wood's lamp and responds better to topical treatment.
Dermoscopy — assesses pigment depth and any vascular component.
Hormone panel — TSH and thyroid antibodies if thyroid dysfunction is suspected.
Skin biopsy — rarely needed, but can confirm the diagnosis in atypical presentations.

Melasma should be distinguished from post-inflammatory hyperpigmentation, solar lentigines, and drug-induced pigmentation — conditions that can look similar but have different causes and treatment pathways.

Treatment options

Treatment is a long-term process. No single intervention cures melasma; the goal is sustained control.

Sun protection — the non-negotiable foundation. Daily broad-spectrum SPF 50 sunscreen is the cornerstone of all melasma management. Without consistent photoprotection, every other treatment has limited and short-lived effect. Tinted sunscreens containing iron oxides are preferred for darker skin types because they also block visible light. Wide-brimmed hats and shade-seeking during peak UV hours (10 a.m.–4 p.m.) add meaningful protection. In Canada, UV Index regularly reaches 7–9 in summer across most provinces — high enough to trigger melasma even on partly cloudy days.

Topical agents. Hydroquinone (2–4%) remains the most studied depigmenting agent; it inhibits tyrosinase, the key enzyme in melanin synthesis, and is used in cycles of 3–6 months. Tretinoin accelerates cell turnover and disperses melanin more rapidly, and is often combined with hydroquinone for greater effect. Azelaic acid (15–20%) inhibits melanin production with a good safety profile and is one of the few options considered safe during pregnancy. Tranexamic acid — available topically, orally, or by injection — is increasingly used for melasma that does not respond to first-line agents. Niacinamide reduces melanin transfer to skin cells and works well as a complementary agent.

Procedural options. For melasma resistant to topical therapy, chemical peels (glycolic, lactic, or salicylic acid) and laser treatments (Q-switched Nd:YAG, fractional lasers) can be effective. These must be used with caution in darker skin types because of the risk of post-inflammatory hyperpigmentation — a complication that can worsen the original problem if the procedure is not well-matched to the patient's skin.

Addressing hormonal triggers. Switching from a combined oral contraceptive to a progestogen-only pill, hormonal IUD, or non-hormonal method often leads to gradual improvement. Melasma from pregnancy frequently fades partially or fully in the months after delivery as estrogen and progesterone return to baseline, though it does not always resolve completely without active treatment.

When to see a clinician in Canada

See a dermatologist or family physician if:

New symmetrical pigmentation has appeared on your cheeks, forehead, or upper lip — particularly during pregnancy or while using hormonal contraceptives
Over-the-counter products have not improved pigmentation after 3–6 months of consistent use
The pigmentation is causing significant distress
You are pregnant and want guidance on which treatments are safe
You are using hormonal contraceptives and have noticed worsening patches

Canadian patients can access dermatology referrals through their provincial health system; wait times vary by province. For those seeking faster access to prescription topicals or a hormonal contraceptive review, virtual care platforms — including Maple, Felix, Cleo, and others — can connect patients with licensed Canadian clinicians who can assess and prescribe where appropriate.

Limitations and open questions

Research is still emerging on the role of visible light (including blue light from screens) in melasma, and current Canadian sun-protection guidelines do not yet specifically address visible-light protection for melasma-prone individuals. The long-term safety and optimal dosing of oral tranexamic acid for melasma have not been fully established, and Health Canada has not issued specific guidance on its use for this indication. Evidence on whether progestogen-only hormonal methods are truly melasma-neutral in all patients is limited — most data come from studies of combined contraceptives. The mechanisms linking thyroid dysfunction to melasma are not fully understood. Finally, there are no large Canadian-specific prevalence studies; most epidemiological data come from Brazilian, Mexican, and Southeast Asian cohorts, which may not fully reflect the Canadian population's diversity of skin types and UV exposure patterns.

Melasma